Barclays analyst Gena Wang initiates coverage on Idera Pharmaceuticals (NASDAQ: IDRA) with a Overweight rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE